Laurus Labs Ltd has recently informed exchanges that the company successfully completed the US Food and Drug Administration (US FDA) audit of its API manufacturing plant in Hyderabad.
The audit resulted in zero Form 483 observations, highlighting Laurus Labs’ dedication to maintaining the highest standards of compliance, safety and quality.
In the exchange filing, the company also shared, “The US FDA inspection, conducted from 9th to 13th September, focused on evaluating the facility’s adherence to global regulatory requirements and best practices. Laurus Labs’ API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing Active Pharmaceutical Ingredients, bolstering the company’s ability to deliver high-quality, innovative pharmaceutical solutions to its global customers.”
